Introduction {#s1}
============

Complex gut microbiome phenotypes shape human nutrition ([@bib72]; [@bib101]; [@bib10]), therapeutic drug responses ([@bib39]; [@bib41]; [@bib53]) and disease susceptibility ([@bib52]). Multi'omic studies suggest that the human gut microbiota can be discretized at the resolution of microbial enzymes ([@bib39]; [@bib105]), species ([@bib41]; [@bib42]), guilds ([@bib48]; [@bib119]) or metabolites ([@bib23]) to characterize a range of human health and disease states. Gut microbial mediated biochemical transformations have consequences for drug treatment efficacy ([@bib53]; [@bib102]; [@bib1]; [@bib115]) and the etiology of inflammatory gastrointestinal diseases ([@bib108]; [@bib3]; [@bib7]; [@bib9]), however despite many examples there exist few unifying principles that govern microbiome impacts on human health.

Some microbiome/drug interactions have been characterized in detail. For example, the inactivation and decreased bioavailability of digoxin, a cardiac glycoside inhibitor, is linked to *cgr* operon expression levels in a single species, *E. lenta* ([@bib41]). Microbial β-glucuronidases mediate the reactivation of the key therapeutic metabolite of irinotecan, a chemotherapeutic prodrug used in the treatment of colorectal cancer, causing toxicity in some patients ([@bib39]; [@bib111]). Notably, diet-derived compounds that are conjugated to glucuronic acid in the human liver and excreted via the biliary route into the GI tract are known substrates for microbial β-glucuronidases ([@bib78]; [@bib88]; [@bib66]).

Many other gastrointestinally-routed drugs share overlapping chemical properties with diet-derived compounds. We understand in detail species-specific metabolism of some discrete chemical structures in dietary compounds, particularly polysaccharides ([@bib71]); however we know little about the potential spectrum of drug metabolism by the microbiome.

Beyond the role of the microbiome in therapeutic drug treatment efficacy and polysaccharide metabolism, we have some mechanistic insight into how microbial metabolism contributes to host immunity. Microbial enzymes mediate the conversion of tryptophan into indole ([@bib91]) and indole derivatives ([@bib2]) that shape human host immune responses ([@bib63]; [@bib8]). Microbe produced indole 3-aldehyde functions as an activating ligand for human host aryl hydrocarbon receptors which are expressed by immune cells ([@bib121]). Indole binding induces IL-22 secretion by innate lymphoid cells, promoting the secretion of antimicrobial peptides that protects the host from pathogenic infection by *Candida albicans* ([@bib121]). Microbial production of short chain fatty acids (SCFAs) from dietary fiber also shapes host immunity, contributing to both innate and adaptive immune system functions ([@bib34]; [@bib29]; [@bib100]).

Host-microbe interactions and phenotypes, ranging from host drug response to host immune response, are thus intimately connected to gut chemical signaling. Beyond these few well understood examples lie a vast space of uncharacterized microbe-drug-diet-phenotype interactions. We propose three key requirements to characterize the dynamics of the gut chemical space and its impact on health. The first is predicting which compounds microbes can metabolize, the second is connecting the chemistry of gut microbes to host phenotypes, and the third is linking gut chemistry to microbial ecology.

Towards the goal of systematically mapping the gut microbial chemistry that contributes to the metabolism of xenobiotics, including therapeutic drugs, recent efforts have used chemical structure-centric approaches to enable high-throughput computational predictions of gut microbe metabolism of drugs ([@bib94]; [@bib68]). These tools represent an important first step towards ecological and mechanistic insights into gut microbiota driven biotransformation of foods and drugs. The second requirement, which has not yet been achieved, is to connect the known and predicted chemistry of gut microbes to host phenotypes. To date, information on human responses to therapeutic drugs is available in disparate databases and formats including FDA Adverse Report System (FAERs) ([@bib14]), the Side Effect Resource (SIDER) ([@bib55]) and DrugBank ([@bib60]). The third requirement, also lacking, is to systematically link gut microbe chemistry to microbial ecology to understand how the distribution of enzymes in populations of microbes facilitates ecological interactions that structure the human gut.

Here, we develop MicrobeFDT, a resource encompassing this 3-step framework that connects compound structure, enzyme function, taxonomy, and toxicity to characterize microbe-diet-drug-phenotype interactions. We organize \~10,000 food, drug, and endogenous compounds by structural similarity. We then link toxicity, enzyme interactions, and the propensity for gut microbes to carry out metabolism on each compound to the structural similarity network. We validate MicrobeFDT computationally by demonstrating that structural similarity is a reasonable proxy for toxicity, enzyme sharing, and coarse-grained functional similarity. We propose, and experimentally validate, active gut microbiome demethylation of an ovarian cancer drug, altretamine, a metabolism that we propose may drive toxicity of this drug. All data is available in the MicrobeFDT database ([MicrobeFDT](https://github.com/kellylab/microbeFDT-neo4j); [@bib40]; copy archived at <https://github.com/elifesciences-publications/microbeFDT-neo4j>).

Results {#s2}
=======

Structural similarity as a metric to organize enzyme/taxonomy/toxicity links between compounds {#s2-1}
----------------------------------------------------------------------------------------------

The foundation of the MicrobeFDT resource is a chemical similarity network linking 10,822 food, drug, and endogenous compounds with PubChem compound identifier (CIDs) ([@bib51]). In the network, nodes designate compounds and edges are weighted by pairwise chemical substructure similarity quantified by comparing PubChem fingerprints ([@bib51]) using the Tanimoto score ([@bib4]) ([Figure 1](#fig1){ref-type="fig"}). The Tanimoto score prioritizes overlap between compounds that share substructures over compounds with shared co-absences ([@bib4]). We hypothesized that compounds with overlapping substructure and physiochemical properties, in which one compound is a known substrate of an enzyme, will be more likely to serve as substrates for the same enzyme. Recent *in silico* approaches to predict enzymatic reactions of drugs in the context of human enzyme catalyzed reactions also employ this hypothesis ([@bib77]; [@bib120]). Substructure-based clustering thus serves as a first step towards synthesizing publicly available information on gut compound chemical diversity and gut microbiome biochemistry.

![MicrobeFDT is a searchable resource of gut microbiome food and drug metabolism with associated toxicities.\
(1) Diet-derived, xenobiotic-derived and endogenous compounds were clustered based on the PubChem fingerprint system ([@bib51]) and the Tanimoto coefficient ([@bib4]). (2) The pairwise similarity matrix forms the basis of the (3) substructure similarity network in which nodes are compounds and links are weighted by substructure similarity. (4) A Z-score based threshold method was used to identify significant chemical similarity relationships between nodes ([@bib5]). (5) The property graph model of nodes and relationships in the network highlights node-relationship pairs that can be queried. Node entities include compounds (blue), uses (orange) and enzymes (green). A compound node can have up to four types of directional relationships: compound pairwise substructure similarity, compound pairwise toxicity similarity, compound treatment use descriptor and compound microbial mediated metabolism descriptor.](elife-42866-fig1){#fig1}

To validate that our network can identify shared metabolism, we developed an in silico prediction model to assign a probability of shared metabolism between compounds based on substructure overlap and the following physiochemical categories: geometry, functional groups, amino acid composition, polarity and hydrophobicity. We find that the probability estimates of compound-pairs sharing an enzyme based on substructure and physiochemical parameters, increase as the substructure overlap score between compound pairs increases ([Figure 2](#fig2){ref-type="fig"}). Weighting compound pair chemical similarity relationships based on substructure similarity is thus a reasonable filtering step to identify compounds that may share metabolism.

![Higher substructure similarity scores between pairs of compounds are associated with higher probability of sharing an enzyme.\
Potential enzyme mediated metabolism of compound pairs is compared with substructure similarity to determine the probability that compounds have an experimentally determined shared enzyme (pink) or no known shared enzyme (blue). The gray vertical dashed line indicates the average cutoff for significance in substructure similarity neighborhood construction. Probability estimates are based on a Bayesian approach for support vector machines implemented in R using the probsvm package ([@bib122]).](elife-42866-fig2){#fig2}

As an example of how the network can reveal shared metabolism we selected compounds in the network with substructure overlap with digoxin, a cardiac glycoside inhibitor. Reduction of digoxin by a human microbiome reductase inactivates the drug, contributing to poor bioavailability in some individuals ([@bib41]; [@bib42]; [@bib64]). Koppel et al., biochemically characterized the capacity of a single flavin- and \[4Fe-4S\] cluster-dependent reductase, *cgr2*, to reduce various substrates with a range of substructure similarity to digoxin ([@bib54]). We identified the substructure overlap between digoxin and compounds in the Koppel et al. study that were evaluated as substrates of Cgr2 enzyme. Among the biochemically assayed compounds ([@bib54]) that are present in the MicrobeFDT network, compounds with substructure similarity scores greater than 0.8 are also substrates for Cgr2. This assessment suggests that for the cgr enzyme substructure based clustering can distinguish experimentally characterized substrates from non-substrates ([Figure 3](#fig3){ref-type="fig"}).

![Substructure similarity range of Cgr2 enzyme susceptible compounds.\
Substructure based clustering distinguishes experimentally characterized substrates from non-substrates of the Cgr2 enzyme. Digoxin clusters with other cardenolides that are experimentally characterized substrates ([@bib54]) for Cgr2 at substructure similarity values greater than 0.8. Compounds that are not substrates of Cgr2 have lower substructure similarity with digoxin; compounds with minimal reduction ([@bib54]) include progesterone and cortisone (substructure similarity \<= 0.63). Color bar intensity increases with compound overlap with digoxin.](elife-42866-fig3){#fig3}

Previous studies have found that structural similarity predicts both toxicity and drug target similarity ([@bib17]). To evaluate whether our network also recapitulates shared drug toxicity we fit a linear regression and computed the effect size to assess the association between substructure similarity and toxicity similarity for therapeutic drugs in our network. We find that structural similarity moderately positively predicts toxicity similarity for therapeutic drug pairs linked by structural similarity overall in the network (r = 0.03116, p\<2.2e-16) ([Figure 4](#fig4){ref-type="fig"}).

![Substructure similarity is predictive of toxicity similarity.\
We evaluated the predictive power of substructure similarity to identify compounds with shared toxicity using a measure of pairwise toxicity defined by [@bib17] and used a linear regression to determine the strength of the association. We find a modest positive correlation between substructure similarity and toxicity similarity that is stronger for more structurally similar compounds.](elife-42866-fig4){#fig4}

Finally, we evaluated how well our compound clustering recapitulates structure-based chemical taxonomy as defined by the ClassyFire ([@bib28]) resource, a comprehensive chemical classification schema, at the level of superclass taxonomy. We found that substructure-based compound clustering, significantly groups compounds within a ClassyFire superclass based on a comparison of the MicrobeFDT network with a randomized network with the same number of nodes and edges (p\<8.06×10--15, Wilcoxon rank-sum test). Compound-pairs at higher substructure similarity share Superclass membership at higher substructure values and at a greater frequency than randomized pairs, indicating that the MicrobeFDT substructure similarity metric can capture established chemical classifications ([Figure 5](#fig5){ref-type="fig"}).

![Compound-pairs share superclass annotation at a greater frequency as substructure similarity scores increase.\
Ratio of compound-pairs substructure similarity with matched and unmatched superclass annotation for all compound pairs represented in MicrobeFDT. Within the hierarchical ClassyFire classification schema, the superclass level annotation represents the second level and includes 31 different structure-based categories ([@bib28]).](elife-42866-fig5){#fig5}

Overlapping structural diversity of food, drug, and endogenous compounds {#s2-2}
------------------------------------------------------------------------

In the network, therapeutic drug structural diversity is embedded within food-derived chemical diversity. For example, drugs share structural similarity with food-derived compounds from a diverse range of classes including benzenoids, lipids, nucleosides and phenylpropanoids ([Figure 6](#fig6){ref-type="fig"}). Food derived compounds also contributed significantly greater molecular structure diversity ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) and higher self-similarity than therapeutic drug compounds (two-sample K-S test 0.49, p value=4.7395e-06).

![The chemical space of the gut microbiome.\
(**a**) Chemical similarity network of food-derived or endogenous compounds (gray circles, \"Other\") and therapeutic drugs (black diamonds, \"Drug\"). Tan edges are weighted by substructure similarity where thicker edges indicate higher substructure similarity. The distribution of compounds in chemical similarity space illuminates regions of low and high chemical substructure overlap between drugs and other compounds. (**b**) Compounds from selected regions of the network are colored by their superclass level taxonomy based on the FooDB chemical structure classification ([@bib116]). Food-derived or endogenously produced compounds are identified with blue circles, therapeutic drugs with red diamonds. Within high-drug density, highlighted regions **1** and **2,** drugs share substructure similarity with food-derived benzenoids, lipids, phenylpropanoids and polyketides. In the low-drug density highlighted region **3**, drugs overlap with organonitrogen compounds and nucleosides. Region **4** includes organonitrogen compounds and nucleosides in addition to lipid-like molecules which have minimal overlap with therapeutic drugs.\
10.7554/eLife.42866.010Figure 6---source data 1.Chemical similarity scores for drug and non-drug compounds.](elife-42866-fig6){#fig6}

Assessing the distribution of enzymatic functions across taxonomic groups {#s2-3}
-------------------------------------------------------------------------

Metabolic functions are not necessarily equally distributed across microbes in the microbiome. For example, as described above, inactivation of digoxin, a cardiac glycoside inhibitor, is linked to *cgr* operon expression levels in a single species, *E. lenta* ([@bib41]; [@bib54]). In contrast, the deconjugation and resulting reactivation of SN-38, the active metabolite of the chemotherapeutic colorectal cancer drug irinotecan, is linked to a phylogenetically diverse guild of microbial β-glucuronidase carrying microbes ([@bib39]; [@bib81]; [@bib112]).

The question arises, how many microbes can perform specific enzymatic functions? Knowing the taxonomic distribution of a function can guide approaches to validate hypotheses of microbiota driven modification of specific therapeutic drug or food compounds. More broadly, addressing this question informs therapeutic approaches for targeting specific enzymes to modulate patient responses to drugs and foods.

In MicrobeFDT, we quantify how many taxa have the capacity to carry out a specific function by applying a modified Simpson index function to compute an Enzyme Commission number-specific dominance (ECs~D~) score for all enzymes present in the network. ECs~D~ scores are based on the abundance of enzymes annotated at the species level across healthy human metagenomes from the Integrative Human Microbiome Project (iHMP) ([@bib83]) and are normalized between 0 and 1. Functions carried out by small numbers of species have values closer to 0 while functions carried out by taxonomically diverse groups have functions closer to 1. Thus, the ECs~D~ indicates how broadly distributed a function is, a crucial metric for (1) understanding how to modify a function in the microbiome and (2) predicting how disruptive to the community modifying a function might be.

To validate ECs~D~ scores we first identified biochemical pathways containing enzymes with high and low taxonomic dominance in the literature. Bacterial synthesis of various B group vitamins including biotin, cobalamin and riboflavin vary in the number of potential producers at the Phylum level ([@bib67]). The most commonly synthesized B vitamin across diverse microbial taxa is riboflavin while vitamin B12 is dominated by Fusobacteria ([@bib67]). The ECs~D~ scores of cobalt-precorrin-2 C(20)-methyltransferase (0.305502) from the anaerobic Vitamin B12 synthesis pathway and riboflavin synthase (0.691618) from the riboflavin synthesis pathway in MicrobeFDT agree with the prior systematic genome assessment and experimental results of [@bib67] ([Figure 7](#fig7){ref-type="fig"}). While most bacteria do not synthesize sphingolipids, sphingolipid biosynthetic capacity has been identified in *Sphingomonas spp*, *Bacteroides* and human intestinal pathogens that synthesize and incorporate sphingolipids into their membranes or target host sphingolipids as a point of entry into host cell types ([@bib43]; [@bib44]; [@bib80]). The low ECs~D~ score of phosphatidate phosphatase (0.007353), an enzyme involved in sphingolipid biosynthesis and metabolism ([@bib80]), mirrors the limited distribution of the sphingolipid biosynthetic capacity across gut microbes.

![Linking enzymatic functions with taxonomic diversity.\
The Simpson index was adapted to describe enzyme-specific taxonomic dominance and diversity based on enzyme abundance in taxonomy-linked gene counts across healthy individuals in the Integrative Human Microbiome Project ([@bib83]). We define a microbial enzyme as high dominance and low taxonomic diversity if its Simpson index value falls below 0.46 (red dotted line), the mean value across all enzymes. Dominance-diversity values for gut microbiota functions that fall above or below the mean are highlighted by gray dashed lines and include the following enzymes and pathways: phosphatidate phosphatase (0.007353), cobalt-precorrin-2 C(20)-methyltransferase (0.305502) from the Vitamin B12 synthesis pathway, β-glucuronidase (0.691618), Acetyl-CoA synthase (0.718163) which is involved in the production of propionate from complex carbohydrates, riboflavin synthase (0.794781) from the riboflavin synthesis pathway and acetate kinase (0.931892) which is involved in acetate production. The shaded regions indicate the range of EDs~D~ values that are one standard deviation above and below the mean and reflect the most broadly distributed functions and most specialized functions.](elife-42866-fig7){#fig7}

Combining chemical and toxicity similarity to predict microbial N-demethylase contribution to drug metabolism and toxicity {#s2-4}
--------------------------------------------------------------------------------------------------------------------------

To provide a practical example of using multiple features of MicrobeFDT to identify uninvestigated microbiota-driven drug toxicity, we searched the network for compounds with high structural and toxicity similarity. Among these compounds were the ovarian cancer drug altretamine ([@bib62]) and the environmental contaminant melamine ([Figure 8](#fig8){ref-type="fig"}). Both melamine and altretamine have toxicity profiles that include diarrhea and renal toxicity ([@bib87]; [@bib123]). Melamine, an industrial compound, has experimentally validated microbiome-mediated toxicity ([@bib123]). Altretamine toxicity, however, has not previously been linked to an individual's gut microbiota. Approximately half of patients taking altretamine orally experience various forms of gastrointestinal toxicity including diarrhea, nausea and/or vomiting ([@bib50]).

![Structure-toxicity relationship between melamine and altretamine suggests a role for microbial N-demethylases in altretamine toxicity.\
(**a**) Substructure overlap between altretamine and its nearest neighbors in MicrobeFDT. A Z-score based threshold of significant overlap indicates that altretamine has both high substructure and (**b**) toxicity overlap with melamine. (**c**) The two compounds are distinguishable by the presence of N-methyl groups.](elife-42866-fig8){#fig8}

Within the network altretamine is linked to microbial N-demethylase enzymes which may remove methyl groups from this compound, potentially leading to similar toxic effects as seen with melamine. We found no published experimental evidence of gut microbiota mediated conversion of altretamine. However, N-demethylases in *Pseudomonas putida CBB5* enable this microbe to grow on caffeine and other purine alkaloids as the sole carbon and nitrogen source; thus annotated N-demethylases in *P. putida CBB5* can act on compounds that are structurally similar to altretamine ([@bib104]). Furthermore, we identify hypothetical proteins homologous to *Pseudomonas putida CBB5* N-demethylases in a subset of healthy human guts ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). We hypothesized that gut microbial N-demethylases may partially or completely N-demethylate altretamine, converting it into metabolites that contribute to patient toxicity.

A first step in validating this hypothesis is to demonstrate that the gut microbiome can demethylate altretamine. We incubated altretamine in a pooled fecal slurry generated from three healthy individuals and monitored altretamine and potential metabolites using LC-MS. We controlled for the formation of spontaneous N-demethylation of altretamine, which has been reported in the literature ([@bib26]), and found that a metabolite that is structurally identical to pentamethylmelamine, a demethylated altretamine metabolite, increases in active fecal microcosms over 48 hr ([Figure 9](#fig9){ref-type="fig"}). In active fecal biotic conditions the metabolite continually increased between time 0 and 48 hr. Killed controls demonstrated an increase in metabolite between 0 and 24 hr, though to a lesser extent than in active fecal microcosms. Notably there was little metabolite formation after 24 hr, indicating that in addition to abiotic N-demethylation, active gut microbes demethylate altretamine to the putative metabolite pentamethylmelamine.

![Fecal microbiomes actively demethylate altretamine.\
Liquid chromatography with tandem mass spectrometry (LC-MS) was used to quantify the formation of (**a**) pentamethylmelamine, an N-demethylated metabolite of altretamine identified in the pooled fecal microbiomes of three healthy unrelated individuals. (**b**) The formation of metabolite 1 at 24 and 48 hr was significantly increased under the experimental condition in comparison to the contribution of spontaneous N-demethylation by an unpaired two-sample Wilcoxon test (\*=P \< 0.05).](elife-42866-fig9){#fig9}

Food derived compounds and non-antibiotic therapeutic drugs with potential antimicrobial properties {#s2-5}
---------------------------------------------------------------------------------------------------

MicrobeFDT suggests an unrecognized role for bile acid-like foods and drugs in altering the composition of the human gut. Conjugated primary bile acids (BA) function as potent detergents and antimicrobial agents capable of dissolving microbial membranes and causing intracellular acidification; bile acid function is linked to specific structural features of these compounds ([@bib47]; [@bib6]). Taurochenodeoxycholic acid (TCDCA) is a taurine conjugated primary bile acid with a diet-tunable concentration in the gut ([@bib86]). Energy drinks, animal protein and fish are rich sources of taurine while vegetarian and vegan diets dominated by fruits, vegetables, legumes and soy are poor sources ([@bib86]). Taurine conjugated bile acids are hypothesized to contribute to the etiology of colorectal cancer by generating hydrogen sulfide during microbial mediated de-conjugation of taurine conjugates ([@bib86]). Conjugated primary bile acids have demonstrated in vitro activity as antimicrobial compounds, for example glycocholic and taurocholic conjugated bile acids are bacteriostatic, inhibiting *S. aureus* growth by decreasing intracellular pH and disrupting the proton motor force ([@bib90]).

Using MicrobeFDT, we identified therapeutic drug and food compounds that are structurally similar to TCDCA; we propose these compounds might have similar antimicrobial effects on the microbiome and we discuss studies from other groups that support this hypothesis ([Figure 10a](#fig10){ref-type="fig"}).

![Food-drug compounds chemically similar to TCDCA are putative antimicrobials.\
(**a**) Chemical structure of taurochenodeoxycholic acid (TCDCA). (**b**) TCDCA-like therapeutic drugs that are susceptible to bile salt hydrolases include finasteride and saxagliptin. (**c**) Non-susceptible TCDCA-like therapeutic drugs include betamethasone, dexamethasone and cortisone. (**d**) TCDCA-like food derived compounds include steviol, lanosterol and tomatidine.](elife-42866-fig10){#fig10}

Bile salt hydrolase (BSH) mediated bile salt deconjugation is one mechanism that gut microbes use to detoxify conjugated primary bile acids ([@bib6]); thus BSH activity may support gut bacterial persistence in face of frequent contact with primary BAs. We first subdivided TCDCA-like antimicrobial compounds based on BSH enzyme susceptibility. BSH enzymes are phylogenetically diverse and abundant across healthy human fecal metagenomes ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}). Among the BSH-susceptible therapeutic drug compounds, we identified known antibiotics such as clindamycin and lincomycin, as well as non-antibiotic prescribed therapeutics such as finasteride, which is used for the treatment of androgenetic alopecia ([@bib69]) and benign prostatic hyperplasia ([@bib19]), and the oral antidiabetic drug saxagliptin ([@bib74]) ([Figure 10b](#fig10){ref-type="fig"}). Notably, in a Wistar rat model of chronic bacterial prostatitis (CBP), finasteride reduces bacterial infection as a single agent and has a synergistic effect with ciprofloxacin through an unknown mechanism ([@bib61]). Through in vitro studies, Chavex-Dozal and colleagues propose a role for finasteride in the prevention of *Candida albicans* biofilm formation and filamentation ([@bib20]). These experimental results support the hypothesis that finasteride may have unrecognized off-target antibiotic effects.

Most TCDCA-like compounds in MicrobeFDT are non-BSH susceptible food-derived compounds. Among the TCDCA-like non-BSH susceptible compounds are oral steroid medications, including dexamethasone and betamethasone ([Figure 10c](#fig10){ref-type="fig"}). The immunomodulatory activities of glucocorticoids, including dexamethasone, involve the activation of genes related to anti-inflammatory cytokines such as IL-10 and proteins that inhibit the pro-inflammatory NFκB signaling pathway ([@bib25]; [@bib45]). Dexamethasone has known anti-microbial properties. For example, dexamethasone has dose-dependent anti-microbial activity against clinically isolated *Streptococcus milleri*, *Aspergillus flavus*, and *Aspergillus fumigatus* in culture, while not killing *Staphylococcus aureus* ([@bib76]). *Pseudomonas aeruginosa* was found to be susceptible to dexamethasone at high concentrations ([@bib76]). Cortisone, which also has significant structural overlap with TCDCA, has been linked to a variety of opportunistic infections by enteric bacterial pathogens, for example an increase in gastrointestinal parasites ([@bib75]) and reactivation of *Chlamydia pneumoniae* ([@bib58]).

Food-derived TCDCA-like compounds include steviol, lanosterol and tomatidine. Steviol is a component of stevia which has antimicrobial properties against *Borrelia burgdorferi in vitro* ([@bib107]), and lanosterol derivatives have antifungal activities ([@bib96]). Tomatidine was recently identified as an antibiotic molecule that inhibits ATP synthesis against *Staphylococcus aureus* ([@bib59]); we hypothesize that the antimicrobial activity of this compound may include intracellular acidification given its structural overlap with TCDCA ([Figure 10d](#fig10){ref-type="fig"}). The network thus identifies compounds with known anti-microbial properties in addition to proposing additional, structurally related compounds with uncharacterized effects. We propose that in addition to modulating immune responses, bile salt-like compounds may selectively alter human microbiomes, again, with unknown consequences for treatment outcomes and health.

MicrobeFDT identifies the diet-derived substrate pool for microbial BGs and candidates for nutritional competition with SN-38G {#s2-6}
------------------------------------------------------------------------------------------------------------------------------

We next applied MicrobeFDT to identify diet-derived substrates of a gut carbohydrate active enzyme, β-glucuronidase. β-glucuronidases play a major role in the toxicity of the colorectal cancer chemotherapeutic prodrug irinotecan (CPT-11), whose active form, SN-38, is inactivated by hepatic glucuronidation and excreted into the gut as the inactive metabolite SN-38 glucuronide (SN-38G) ([@bib111]; [@bib103]). Microbial β-glucuronidases hydrolyze the glucuronide group, releasing the aglycone SN-38 into the intestinal environment ([Figure 11a](#fig11){ref-type="fig"}). Deconjugation promotes epithelial damage and severe diarrhea in some patients and in mouse models ([@bib111]; [@bib103]; [@bib99]).

![Microbial β-glucuronidase potential substrate pool of compounds structurally similar to SN-38G.\
(**a**) SN-38G conversion to SN-38 in the gut is mediated by microbial β-glucuronidases. (**b**) The substrate pool for β-glucuronidases with above threshold substructure overlap with SN-38G are members of a diverse range of chemical structure superclasses as defined by FooDB chemical ontology ([@bib117]). (**c**) These compounds include glucuronidated food-derived compounds (purple), endogenous glucuronides (tan) and other non-glucuronides (blue).](elife-42866-fig11){#fig11}

We previously demonstrated that individual human fecal samples have variable capacities to deconjugate SN-38G ([@bib39]). Identifying the full substrate pool of β-glucuronidases is thus important for 1) understanding how diet contributes to β-glucuronidase abundance and expression levels in the gut and 2) to enable novel therapeutic strategies such as nutritional competition.

Some food compounds may be preferred substrates for microbiome β-glucuronidases which would otherwise deconjugate SN-38G. If true, one could potentially alleviate toxicity associated with the deconjugation of SN-38G via nutritional competition with a preferred substrate. Therefore, we scanned the chemical similarity module containing SN-38G for dietary compounds that may serve as alternative substrates for microbial β-glucuronidases. Most compounds identified as significantly similar to SN-38G were food derivatives or other constituents ([Figure 11b](#fig11){ref-type="fig"}). Among these targets were flavonoids such as baicalin and scutellarin which are widely distributed in plants ([@bib56]) ([Figure 11c](#fig11){ref-type="fig"}). We propose that these compounds may compete with SN-38G for turnover by microbial β-glucuronidases and are a potential avenue for decreasing the adverse drug responses associated with irinotecan administration.

Discussion {#s3}
==========

The chemical space of the human gastrointestinal tract ecosystem is shaped by host dietary intake, xenobiotic exposure, and host and gut microbiome derived products. In turn, diet shapes the composition and potential niches of organisms within human gut microbiomes. A combination of compound, host, and microbiome features influence potential microbial metabolism. Examining these features individually cannot reliably infer clinical phenotypes associated with microbiome/compound interactions. Two molecules may have the same toxicity profile but very different biochemistry, for example. Automated enzyme annotation may be incorrect, and compound structural similarity is often insufficient to predict substrate preferences. Finally, enzymes that carry out a reaction associated with a patient phenotype may be unevenly distributed across microbes and across human microbiomes. MicrobeFDT is designed to overcome some of these limitations by enabling a more holistic analysis of toxicity, structure, metabolism and ecology. We used a combination of network features to successfully predict the novel microbial metabolism of the cancer drug altretamine.

Metabolomics data indicate active demethylation of altretamine by fecal slurries but cannot propose a mechanism by which microbial activity metabolizes this compound. MicrobeFDT suggests that altretamine is a putative substrate of microbial N-demethylases. Microbe-mediated N-demethylation reactions, and the subsequent release of N-methyl groups, occur as a part of amino acid and nucleotide metabolism ([@bib31]). Notably, diet is a source of amino acids which are derived in part from metabolism of dietary choline, carnitine and legumes, and have physiological functions for bacteria including osmoprotection and incorporation into bacterial flagellin proteins and lipid membranes ([@bib36]). Amino acid-specific bacterial N-demethylases have been identified but are poorly characterized ([@bib113]). Additionally, fecal and species specific N-demethylation has been observed for other therapeutic drugs and commonly ingested compounds such as caffeine, which clusters with altretamine in the network due to its structural similarity ([@bib104]; [@bib16]; [@bib22]; [@bib24]). N-demethylases can act on chemically diverse substrates ([@bib113]; [@bib15]). Given this body of evidence, we propose N-demethylases may demethylate altretamine partially or completely, creating metabolites that are toxic to patients.

Human gut metagenomic data indicate that Rieske family oxidative N-demethylases are carried by a small, phylogenetically conserved set of gut taxa, with notable inter-personal variation. That these enzymes require oxygen may make them more relevant during disruptions to gut homeostasis when oxygen becomes available, such as colonic crypt hyperplasia caused by injuries to the intestinal epithelia ([@bib65]). Finally, we note that N-demethylation in the gut may be relevant for differences in individual metabolism of numerous other compounds such as the cancer drug tamoxifen, the widely used antihistamine diphenhydramine, and theobromine, a plant alkaloid found in foods. While is possible that N-demethylation is enzyme independent or that enzymes annotated with other functions are responsible for this activity, MicrobeFDT provides a clear path forward for mechanistic studies of N-demethylation in the gut.

Beyond predicting the toxicity or function of gut compounds, MicrobeFDT identifies the larger substrate pool for enzymes involved in drug metabolism. For example, shared conjugation patterns may represent a clinically relevant way to group compounds that share microbial enzymatic processing. As an example, compounds inactivated by glucuronidation are susceptible to microbial β-glucuronidase-mediated reactivation. We used MicrobeFDT to identify compounds structurally similar to the conjugated, detoxified irinotecan metabolite SN-38G and found dietary substrates that may interact with similar β-glucuronidases that this drug interacts with. Structurally similar compounds may act competitively -- via inhibition of SN-38G turnover by higher priority β-glucuronidase substrates or synergistically -- via substrate inducible transcriptional upregulation of β-glucuronidase enzymes. A person consuming a large amount of the plant-based compound scutellarin as part of a supplement, for example, might be inadvertently modulating the effects of their cancer therapy.

Outside of drug metabolism, β-glucuronidases mediate deconjugation and enterohepatic circulation of estrogens, impacting the human host total estrogen burden ([@bib93]; [@bib57]). It has been hypothesized that β-glucuronidase deconjugation may result in greater absorption of estrogens and thus influence the development of estrogen-driven cancers including breast, ovarian and endometrial cancers ([@bib93]; [@bib57]). Our network is useful for developing mechanistic hypotheses targeting how diet and the microbiome jointly act as moderators of estrogen-driven cancers, and to suggest opportunities for diet-based modulation of total estrogen levels.

An important step towards characterizing the role of the gut microbiome in shaping individual responses to foods and drugs is identifying how gut microbiome metabolism varies from compound to compound and how this metabolism relates to inter-personal variation in diet or drug responses to specific compounds. To tackle this challenge, we add the context of taxonomic diversity to the predicted impact of microbial on specific targets by quantifying enzyme specific taxonomic dominance and diversity with a novel metric, the ECs~D~ score. This score distinguishes enzymatic activities carried out by single species or few taxa, such as N-demethylase activity, from those where many taxa may contribute, such as β-glucuronidase and bile salt hydrolase activity. The ECs~D~ score is a readout of potential substrate metabolism at the community level that can be linked to inter-personal variation in gut function and phenotypic outcomes.

The structural similarity network that underlies MicrobeFDT could be improved by using compound atom and bond connectivity information as an additional filtering step for compounds of interest, for example by using information from the SMARTS molecular pattern matching language ([@bib21]). SMARTS can be used to specify sub-structural patterns in molecules; these patterns could be added to MicrobeFDT as an additional information source indicating potential active moieties in compounds.

MicrobeFDT does not predict substrate specificity for microbiome enzymes; available data and methods are not sufficient to achieve this goal. Enzyme promiscuity also shapes the probability that two chemically overlapping compounds will be processed by the same enzyme. A future improvement to our resource could extract data from resources like RetroRules ([@bib30]), which uses SMARTS strings to define reaction rules, or utilize the Promis server measure of enzyme multifunctionality ([@bib18]) to further support a user's ranking of hypothesized compound-enzyme interactions.

It must be noted that the set of diet-derived and xenobiotic compounds that form the basis of the network is a non-exhaustive representation of the gut chemical landscape. Efforts to characterize the gut chemical space using metabolomics approaches including mass spectrometry and nuclear magnetic resonance spectroscopy will play key roles in elucidating a fuller gut chemical landscape ([@bib110]; [@bib116]). MicrobeFDT does not address the issue of compound concentrations in the gut, which are vital to assess likely physiological effects. Lastly, MicrobeFDT is limited to enzymes in KEGG, and does not address the many hypothetical enzyme sequences identified through metagenomic sequencing. Despite these limitations, MicrobeFDT highlights areas of known gut chemical space for which our understanding of microbial processing is limited and is a powerful tool to guide mechanistic investigations into diet-drug-microbiota interactions.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                Designation                    Source or reference   Identifiers              Additional information
  (species) or resource                                                                                      
  ---------------------------- ------------------------------ --------------------- ------------------------ -----------------------------
  Biological sample\           fecal sample                   other                                          fecal sample obtained\
  (community\                                                                                                from three healthy\
  microbiota, feces)                                                                                         adults

  Chemical\                    altretamine                    Sigma                 Pubchem_ID:329748966;\   prepared in DMSO,\
  compound, drug\                                                                   CAS_No:645-05-6          0.1 mM final\
  (altretamine)                                                                                              concentration in\
                                                                                                             fecal slurry

  Other                        Brain Heart\                   Himedia               Himedia:M210I            
                               Infusion broth                                                                

  Chemical\                    DMSO                           MP Biomedicals        MP:191418;\              
  compound\                                                                         CAS_No:67-68-5           
  (Dimethyl sulfodixe)                                                                                       

  Chemical\                    Melamine-triamine-(^15^N~3~)   Sigma                 Pubchem:329758619;\      prepared in DMSO,\
  compound\                                                                         CAS_No:287476-11-3       400 nM final concentration\
  (Melamine-triamine-(15N3))                                                                                 in analytical sample
  ----------------------------------------------------------------------------------------------------------------------------------------

MicrobeFDT pipeline {#s4-1}
-------------------

The MicrobeFDT graph database encodes heterogeneous information on the interactions between compounds and microbial enzymes in the gut chemical landscape, highlighting the following four relationships across 13,440 nodes (10,822 xenobiotic, diet-derived and human gut endogenous compounds, 2062 microbial enzymes and 525 therapeutic drug use labels) defined from publicly available data directly or computed: (1) compound-compound substructure similarity; (2) compound-compound toxicity similarity; (3) microbial enzyme-compound interactions; and (4) drug-indication associations. The database is implemented in Neo4j (<https://neo4j.com/>) and can be queried through the Cypher Query Language. Through graph-based searches users can query the network based on node or relationship features. MicrobeFDT can be accessed [here](https://github.com/kellylab/microbeFDT-neo4j) ([@bib40]).

Publicly available datasets and resources used as inputs for the network {#s4-2}
------------------------------------------------------------------------

The SIDER 4.1 side effect resource is a database of approved medicines and their known adverse reactions ([@bib55]). Drugs from this database with pharmacokinetic profiles that involve entry into the gastrointestinal tract were identified through literature mining and manual curation and indexed by their PubChem CID identifier ([@bib51]). Drug use annotations were based on the WHO Anatomical Classification System ([@bib98]). FooDB (<http://foodb.ca/>) ([@bib117]), a database containing raw food component structures, biological interactions and chemical properties was the source of food components linked to PubChem CID identifiers. ClassyFire was used to annotate all xenobiotic and food derived compounds with a shared chemical taxonomy ([@bib28]).

To link microbial enzymes to the set of compounds they metabolize we used KEGGREST (v1.14.1) to retrieve KEGG compound identifiers with links to Enzyme Commission numbers, metabolic modules and pathways, and presence in either organisms listed as microbial or *Homo sapiens* ([@bib106]). Enzyme abundance data across human metagenomes were determined based on the total abundance of each enzyme in the healthy participants of the Human Microbiome Project. This data was extracted from the Integrated Microbial Genomes database ([@bib70]). Enzyme specific dominance scores (ECs~D~), which is a measure of the number of different species that carry a specific enzyme, were computed based on species-specific enzyme abundance data from healthy individuals from the Integrative Human Microbiome Project ([@bib83]).

Construction and assessment of the drug-food chemical similarity network {#s4-3}
------------------------------------------------------------------------

### Chemical similarity calculation {#s4-3-1}

To determine the pairwise chemical substructure similarity between all compounds we used the PubChem 2D molecular fingerprint ([@bib51]). The fingerprint is an 881 dimension binary vector in which each bit represents a specific element, functional group, ring system or other discrete chemical entity ([@bib51]). Similarity was defined by the Tanimoto coefficient of the molecular fingerprint representations present between two compounds ([@bib4]).

### Network construction {#s4-3-2}

Similarity scores are percentages of substructure overlap between pairs of compounds and have values between 0 to 1. Similarity scores are filtered such that compound pairs with less than 0.3 substructure similarity were removed. These pairwise similarity scores formed the basis of the undirected chemical similarity network, where nodes represent compounds and edges represent substructure similarity score.

### Network filtering {#s4-3-3}

To cluster compounds in the network based on substructure similarity we used the Walktrap community detection method ([@bib82]) implemented in R/igraph v.1.1.1 ([@bib85]). Within a community, significant similarity scores were defined as those with Z-scores of 1 standard deviation or greater away from the mean ([@bib5]).

### Assessment of compound substructure-based clustering recapitulation of chemical ontology {#s4-3-4}

The MicrobeFDT substructure similarity network is defined by the Tanimoto coefficient of the PubChem 2D molecular fingerprint representations between two compounds ([@bib51]; [@bib4]). To assess how well compound substructure-based clustering recapitulates chemical ontology we compared network features between the MicrobeFDT substructure similarity network and randomized network with the same number of nodes, edges and labels. Each compound label includes a ClassyFire ([@bib28]) schema derived hierarchical set of chemical descriptors. The chemical similarity network was rendered in Cytoscape using NetworkRandomizer ([@bib72]). Using the Wilcoxon rank-sum test we compared superclass level chemical descriptors across connected compounds between the real and random network. For the MicrobeFDT network, we also computed the ratio of compounds pairs with matched Superclass annotation to unmatched annotations for all pairs with the same substructure score to assess the relationship between substructure similarity and shared chemical ontology.

### Predicting the probability of association of compound pairs both serving as substrates for an enzyme based on substructure and physiochemical parameters {#s4-3-5}

Each compound pair was assigned one of two labels, associate or non-associated, based on whether both compounds are substrates for the same enzyme (associated) or not (non-associated), given compound-enzyme relationships in the KEGG database ([@bib49]). The DataWarrior program ([@bib89]) was used to identify the following parameter categories for each compound: geometry, functional groups, aromaticity, amino acid composition, polarity and hydrophobicity. In order to translate compound pair substructure and physiochemical parameters into a probability of overlapping metabolism we used a machine learning approach for generating probability estimates for multi-class classification problems ([@bib122]; [@bib118]). Briefly, this approach builds a multi-class prediction model by using pair-wise coupling. We then implemented the prediction model using the probsvm package in R using a one-vs-one decomposition scheme ([@bib122]).

### Assessing toxicity similarity {#s4-3-6}

Toxicity similarity was computed as described by Campillos and colleagues ([@bib17]) with three key steps: (1) extraction and standardization of side effect concepts across drugs of interest; (2) weighting of unique side effect concepts based on frequency of occurrence and correlation with other side effects; and (3) computation of pair-wise toxicity similarity between drugs based on weighted side-effect concept values. Briefly, Campillos et al. curated a dictionary of side-effects based on the Concepts of the Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART) ontology ([@bib109]). Side-effect information on therapeutic drug package labels was identified from publicly available sources and searched against this dictionary such that all unique side effect concepts per drug were based on COSTART ontology. For our analysis we used the side effect labels for therapeutic drugs of interest that were extracted from the Medical Dictionary for Regulatory Activities ([@bib13]), which is an updated replacement of COSTART, and made publicly available at the download page for SIDER 4.1 which can be found [here](http://sideeffects.embl.de/media/download/meddra_all_label_indications.tsv.gz).

In Campillos et al., each side effect concept was given a rarity score which is the frequency at which it is found across all drug side effect lists. To account for co-dependence between side effects Campillos and colleagues also determined the correlation between all side effects based, using the Tanimoto score between pairs of side effects. This measure is based on how many drugs share a given side effect relative to the number of drugs that have either. The resulting matrix was used as input for the Gerstein-Sonnhammer-Chothia Algorithm ([@bib35]), to output a score for each concept that down weights concepts that are redundant. We used a publicly available implementation of this algorithm in R available [here](https://github.com/antoine-lizee/R-GSC). Pair-wise toxicity similarity between drugs was computed based on summing the products of weights over all shared side effect concepts between drug pairs. We fit a linear regression to determine whether there is a linear relationship between compound pair substructure similarity and toxicity similarity.

Taxonomic signatures of microbial enzymes {#s4-4}
-----------------------------------------

For each enzyme, we computed an enzyme commission number-specific dominance (ECs~D~) score. This score is an application of the Simpson's index, which is particularly sensitive to sample evenness ([@bib27]), and describes the dominance and diversity profile of species carrying the enzyme ([@bib79]). The taxa-specific enzyme abundance information is based on data collected as a part of the integrative Human Microbiome Project (iHMP) ([PRJNA306874](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA306874)) ([@bib83]). ECs~D~ scores are reported as Simpson index measure ([@bib97]) subtracted from one, as implemented in the phyloseq R package ([@bib73]). In this implementation, the Simpson dominance index per enzyme defined by its enzyme commission number (D(EC)) is computed such that *n* is number of individuals of each species that carry the enzyme and *N* is the total number of individuals of all species that carry the enzyme (1). For better interpretability, the dominance scores are subtracted from 1 (2).$$D\left( EC \right) = \frac{\Sigma n\left( n - 1 \right)}{N\left( N - 1 \right)}$$$${EC_{SD}} = 1 - D\left( {EC} \right)$$

Thus, enzyme functions carried out by small numbers of microbes have values closer to 0 while functions carried out by taxonomically diverse groups have functions closer to 1. 

Altretamine microbiome turnover validation {#s4-5}
------------------------------------------

### Collection and preparation of fecal samples {#s4-5-1}

Fresh fecal samples were provided by three healthy adult men aged 23--30 with no history of antibiotics for 6 months prior to the study. The study was approved by the Albert Einstein College of Medicine Institutional Review Board. Samples were deposited, immediately stored on ice, and processed within 1 hr. One gram stool from each donor was added to 300 mL BHI supplemented with 0.5% glucose (weight/volume) and homogenized. The final fecal slurry was thus comprised of the pooled feces of the three donors at 1% w/v.

### Altretamine metabolism {#s4-5-2}

Fecal slurry cultures were incubated at 37°C in the dark under aerobic conditions. Altretamine stock was prepared in DMSO. Experimental cultures received a final concentration of 100 µM altretamine in DMSO and were prepared in triplicate. Triplicate heat-killed and denatured cultures were autoclaved three times on successive days and also received 100 µM altretamine in DMSO after the third autoclave. Background cultures received fecal slurry and DMSO but no altretamine. To determine matrix effects of altretamine in the media, a sterile media control was amended with 100 µM altretamine in DMSO. Cultures were sampled, immediately snap-frozen in liquid N~2~ every 24 hr, and stored at −80°C until analysis.

### Altretamine and metabolite quantification {#s4-5-3}

Samples were thawed, centrifuged, and 100 µL aliquots were added to 900 µL 80% methanol. Melamine-triamine-(^15^N~3~) was used as internal standard. Altretamine and metabolites were identified using LC/MS (Waters Acquity LC system and Waters Xevo TQ MS). Liquid samples were diluted 1:50 in 80% methanol with melamine-triamine-(^15^N~3~) as internal standard. Each sample was injected 3 times at 5 mL/injection. Separation was performed on an ACE2 C18 column set to 45°C with 0.1% formic acid in 5% methanol (A) and 0.1% formic acid in methanol (B). Elution occurred at 0.35 ml/min with 100% A for 1 min, followed by a 1.5 min linear gradient from 100% A to 95% B, and finally 100% B for 1 min. The voltage was set to 0.044 kV.

Phylogenetic trees {#s4-6}
------------------

### N-demethylase phylogenetic tree {#s4-6-1}

N-demethylases from *Pseudomonas putida* CBB5 (*ndmABCD*) ([@bib104]) and *Sphingobium* sp. strain YBL2 (*pdmAB*) ([@bib37]), both containing a Rieske non-heme iron oxygenase component, catalyze the N-demethylation of phenylurea herbicides and purine alkaloids, respectively; and range in size from 318 to 364 amino acids ([@bib104]; [@bib37]; [@bib95]). We clustered bacterial N-demethylase sequences described by Summers *et al.,* and Tao *et al.,* as well as protein sequences of \>= 200 amino acids in length pulled based on text annotation from the RefSeq database ([@bib84]) at 95% identity using the UCLUST algorithm ([@bib33]). The resulting 84 N-demethylase protein sequences served as a protein database which was mapped against the protein calls of healthy adult participants from the Human Microbiome Project (HMP) ([PRJNA43021](https://www.ncbi.nlm.nih.gov/bioproject?term=PRJNA43021)) using the UBLAST algorithm ([@bib33]) and e-value cutoff of e-40. N-demethylase hits of 200 amino acids or greater formed the basis of a phylogenetic tree which was constructed by aligning the protein sequences using MUSCLE with default parameters ([@bib32]). Aligned sequences were trimmed at 70% identity and phylogenetic trees were built with PhyML ([@bib38]) with 100 bootstrap replicates, a JTT model of substitution, and otherwise default parameters. The trees were visualized using the packages ggpplot2 ([@bib114]) and phyloseq ([@bib73]) in R ([@bib85]). Each branch was colored based on the phylum level classification of the protein, marked by similarity to the experimentally characterized N-demethylase genes *ndmABCD* and *pdmAB* and by the normalized number of total hits found across individuals in the HMP. Black circles indicate bootstrap values of 80/100 or better.

### Bile salt hydrolase phylogenetic tree {#s4-6-2}

We identified bile salt hydrolase protein sequences based on text annotation from the RefSeq database ([@bib84]) and developed a curated database of protein sequences that were clustered at 95% identity using the UCLUST algorithm ([@bib33]) resulting in 300 bile salt hydrolase protein sequences with a minimum amino acid length cutoff of 300. Bile salt hydrolase subunits can range in length up to 518 amino acids in the literature ([@bib11]; [@bib12]; [@bib92]). Sequence mapping against the HMP ([@bib46]), alignment and tree construction were carried out as described for the N-demethylases with the following exception: each branch representing a unique bile salt hydrolase sequence was marked by the presence or absence of reported activity in the literature.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for sending your article entitled \"The gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs\" for peer review at *eLife*. Your article has been evaluated by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, with strong expertise in microbiome research, analytical chemistry, and comparative genomics, respectively, and the evaluation has been overseen by Wendy Garrett as the Senior Editor.

There was a consensus that the identified topic represents a major gap in scientific knowledge and the toolkit established here could provide a valuable resource to the microbiome community. These findings could have broad implications for the field and provide the inspiration and framework for the development of more sophisticated follow-on algorithms. However, the reviewers also raised multiple technical considerations that limited our enthusiasm for publication at this time.

The full reviews are attached below and I have briefly summarized the major concerns here.

1\) Lack of computational or experimental validation. The specific examples mentioned as potential future directions do not help that much in evaluating the overall reliability of the predictions made by this approach. The authors should consider whether or not there are suitable gold-standards; for example, the \>50 drugs that are already known to be metabolized by human gut bacteria. Alternatively, they could use as positive controls structural analogs like altretamine and melamine, to see if these chemical pairs always result in similar predictions. The authors might also test if their unbiased clustering recapitulates established chemical classes. In addition to these more global analyses of specificity, sensitivity, and precision, we would like to see at least one of the novel predictions validated experimentally (if possible within the time frame).

2\) Structural similarity could be misleading. The major caveat to this approach is that overall similarity can be thrown off by differences in parts of the molecules that are irrelevant for the enzymatic activity. This can lead to false positives (compounds with similar overall structure but differences in the relevant sub-structure) and false negatives (compounds with different R groups but the same core chemical motif). While solving this problem may be beyond the scope of this analysis, we would like to see it acknowledged and some analysis to determine how big a problem this is for the current set of predictions.

Numerous research groups work in this area with a higher degree of sophistication, and likely accuracy, than this paper describes (see citations from reviewer 2). Each of the tools above allows compounds to be linked to reactions; none are mentioned in this paper; and none of them rely on simply using a chemical fingerprint as the likelihood that a drug would participate in a chemical reaction. Chemical fingerprints are not intended for asserting that a molecule would be compatible with a chemical reaction. If we understand the algorithm correctly, we don\'t think it is appropriate for scoring biochemical-reaction promiscuity. We recommend completely overhauling this part of the algorithm.

In the examples that the authors show, leucovorin is strongly clustered with ambenonium which differ in structure. Similarly, metformin and atretamine are very different molecules -- even though they are rich in Nitrogen. Furthermore, not every chemical moiety can be undone-just because a molecule has a methyl group doesn\'t mean that it can be demethylated.

3\) Clustering by toxicity could also be misleading. The logic here is not clear, since there could be many reasons for why two molecules show the same toxicity profile -- most of which will have nothing to do with the microbiome or with metabolism more broadly. For example, two completely different antidiabetic drugs may have the same side effect, hypoglycemia. A diuretic and a smooth muscle relaxant may have the same side effect, hypotension, etc.

4\) ECs are broad groups of enzymes that do not adequately capture substrate preferences. It\'s unclear to us how the EC analysis would be used in practice. For example, let\'s consider the case of altretamine and N-demethylases. These enzymes are widespread in bacterial genomes and have broad substrate scope as a family. Which one (if any) can metabolize the drug? Just because an enzyme has an EC annotation of ligase, hydrolase, oxidoreductase, doesn\'t mean that a molecule with certain functional groups can be a substrate to it. It doesn\'t even mean that it is correctly annotated.

Reviewer \#1:

Guthrie and Kelly present an interesting structure-based analysis of food and drugs with the goal of predicting gut microbial biotransformation. This dataset has great potential as a resource to the community. The major problem is the lack of either computational or experimental validation, making it unclear how reliable the inferences are, and thus limiting their utility. There are also some concerns about the assumptions made by this method that could lead to false positives and false negatives.

Major issues:

1\) Lack of validation. While I really enjoyed reading the specific examples mentioned as potential future directions, they do not help that much in evaluating the overall reliability of the predictions made by this approach. The authors should consider whether or not there are suitable gold-standards; for example, the \>50 drugs that are already known to be metabolized by human gut bacteria. Alternatively, they could use as positive controls structural analogs like altretamine and melamine, to see if these chemical pairs always result in similar predictions. The authors might also test if their unbiased clustering recapitulates established chemical classes. In addition to these more global analyses of specificity, sensitivity, and precision, I would like to see at least one of the novel predictions validated experimentally.

2\) Structural similarity could be misleading. The major caveat to this approach is that overall similarity can be thrown off by differences in parts of the molecules that are irrelevant for the enzymatic activity. This can lead to false positives (compounds with similar overall structure but differences in the relevant sub-structure) and false negatives (compounds with different R groups but the same core chemical motif). While I realize that solving this problem is beyond the scope of this analysis, I would like to see it acknowledged and some analysis to determine how big a problem this is for the current set of predictions.

3\) ECs are broad groups of enzymes that do not adequately capture substrate preferences. It\'s unclear to me how the EC analysis would be used in practice. For example, let\'s consider the case of altretamine and N-demethylases. These enzymes are widespread in bacterial genomes and have broad substrate scope as a family. Which one (if any) can metabolize the drug?

4\) The section on antibiotics (subsection "MicrobeFDT identifies food derived compounds and non-antibiotic therapeutic drugs with putative antimicrobial properties") was interesting, but doesn\'t fit the scope of this paper. Need to either remove this section or reframe the goal of this study. I\'d vote for the former, since it is currently lacking in novelty or experimental validation.

Reviewer \#2:

The manuscript, \"The gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs\", herein referred to as \"this paper\", describes a creative computational link between drugs, metabolites, genes and microbes. The narrative on the importance of linking the compounds we eat whether drugs or from food with the reactions in the gut performed by microbes is almost worth publishing on its own. It was enjoyable to read such a well thought out and presented essay on this topic. In regards to the actual research described in the paper, I have two major concerns: the validity of their major claims and using chemical fingerprint as a proxy for reactivity given alternative approaches.

To see if other e*Life* manuscripts contained more or less validation of computational methods, I searched *eLife* for \"chemical fingerprint\". There were 43 results. Of these, the following three are in the same general area as this paper.

-- Prediction of enzymatic pathways by integrative pathway mapping: https://doi.org/10.7554/eLife.31097

-- Systematic integration of biomedical knowledge prioritizes drugs for repurposing: https://doi.org/10.7554/eLife.26726

-- Digitizing mass spectrometry data to explore the chemical diversity and distribution of marine cyanobacteria and algae: https://doi.org/10.7554/eLife.24214

In these three prior manuscripts, the amount of validation varies quite a lot. \"Prediction of enzymatic...\" includes enzymology, crystallography, and metabolomics to validate their method for a specific pathway; \"Systematic integration...\" uses only out-of-sample validation set; and \"Digitizing mass spectrometry...\" uses the identification of a single novel compound to suggest validation of the overall method. My initial reaction to this paper was that its an important application of a creative idea, but the degree to which the network they\'ve built is validate is insufficient. However, in comparison to the prior papers in *eLife*, I think the amount of validation in this paper is only slightly lower than what is already in the journal. Testing the predictions of their network would be a significant endeavor.

Nevertheless, this paper makes the following claims:

\"Together, our resource identifies novel gut microbiome-mediated metabolic activity and associated adverse responses that can be used to identify targets for experimental validation and to generate new hypotheses about microbe-drug-diet interactions in human health and disease. We demonstrate the utility of this resource with the following three novel insights into microbial drug metabolism and human health.\"

And the following speculations:

\"We propose uninvestigated microbiota mediated metabolisms that may drive toxicity of therapeutic drugs, we highlight non-antibiotic compounds that may have antimicrobial properties, and we identify drug-food interactions with microbial enzymes that may influence drug efficacy and microbiome function.\"

For all claims made in the paper, my belief is that a validated approach should be used. Therefore, I recommend the authors validate their approach prior to making such claims. In the scope of this journal, speculation and suggestion is ok as long as it is worded appropriately.

I\'m worried about relying on a chemical fingerprint to assert that a drug would react in place of a metabolite in a known biochemical reaction. Numerous research groups work in this area with a higher degree of sophistication, and likely accuracy, than this paper describes. I am aware of the following works, but there are likely many more.

-- in vivo/In Silico Metabolites Database (IIMDB)

-- RetroPath and RetroRules (http://www.jfaulon.com/)

-- MINEs: open access databases of computationally predicted enzyme promiscuity products for untargeted metabolomics

-- MAGI: (https://magi.nersc.gov)

-- ATLAS of Biochemistry: A Repository of All Possible Biochemical Reactions for Synthetic Biology and Metabolic Engineering Studies

-- Nontargeted in vitro metabolomics for high-throughput identification of novel enzymes in *Escherichia coli*. Nature Methods (2016)

Each of the tools above allows compounds to be linked to reactions; none are mentioned in this paper; and none of them rely on simply using a chemical fingerprint as the likelihood that a drug would participate in a chemical reaction. Perhaps the most directly applicable to this paper would be RetroPath/RetroRules. It uses a considerably more elegant means to assert that a drug would participate in a reaction. Chemical fingerprints are not intended for asserting that a molecule would be compatible with a chemical reaction. If I understand your algorithm correctly, I don\'t think it is appropriate for scoring biochemical-reaction promiscuity. I recommend completely overhauling this part of the algorithm.

Reviewer \#3:

In the submitted manuscript, Guthrie and Kelly propose a resource (MicrobeFDT) that constructs interacting networks of drugs, endogenous, and dietary molecules based on their structural similarity, known toxicities, and possible metabolizing enzymes.

The manuscript was written in a very convoluted manner, with intertwined logic, design, and results (and even literature references), making it difficult to follow. There is very limited detail about the approach itself and actual analyses. The authors describe three main tasks:

1\) Define the chemical space of xenobiotics that the human microbiome is exposed to. They use similarity in chemical substructure to achieve this goal, based on previously developed algorithms and metrics. In the one example that the authors show, leucovorin is strongly clustered with ambenonium -- which is clearly a problem! Similarly, metformin and atretamine are very different molecules -- even though they are rich in Nitrogen!

2\) Cluster molecules based on their reported toxicities. The logic here is not clear, since there could be many reasons for why two molecules show the same toxicity profile -- most of which will have nothing to do with the microbiome. For example, two completely different antidiabetic drugs may have the same side effect, hypoglycemia. A diuretic and a smooth muscle relaxant may have the same side effect, hypotension, etc.

3\) Identify biochemically relevant and functionally plausible microbe-compound interactions. This section was not clear at all to the reviewer. Even the essence for how microbial enzymes are linked to the network of molecules is not described clearly. In one section, the authors mention: \"structure-activity filtering, the user establishes the search target based on prior knowledge of structure-activity relationships (for example, a compound with a methyl group that is susceptible to microbial methylases)\". Why would a methylated compound be susceptible to methylases? Maybe it is a typo and the authors meant demethylases? Even in this case, the logic is very unclear. Not every chemical moiety can be undone, and just because a molecule has a methyl group doesn\'t mean that it can be demethylated. Also, there is a fundamental misunderstanding here for the basics of biochemistry. Just because an enzyme has an EC annotation of ligase, hydrolase, oxidoreductase, doesn\'t mean that a molecule with certain functional groups can be a substrate to it. It doesn\'t even mean that it is correctly annotated. Basing conclusions on these general annotations is meaningless.

Overall, the reviewer does not see the value of the tool developed here, based on fundamental issues with the logic of the design itself, as well as a lack of clarity in the description of the method and analysis performed. The examples listed in the text are either obvious (e.g., glucoronidated molecules will probably get deglucoronidated) or completely speculative (steroids are antibiotics), despite being \"supported\" by cherry-picked citations.

10.7554/eLife.42866.022

Author response

> Thank you for sending your article entitled \"The gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs\" for peer review at eLife. Your article has been evaluated by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, with strong expertise in microbiome research, analytical chemistry, and comparative genomics, respectively, and the evaluation has been overseen by Wendy Garrett as the Senior Editor.
>
> There was a consensus that the identified topic represents a major gap in scientific knowledge and the toolkit established here could provide a valuable resource to the microbiome community. These findings could have broad implications for the field and provide the inspiration and framework for the development of more sophisticated follow-on algorithms. However, the reviewers also raised multiple technical considerations that limited our enthusiasm for publication at this time.
>
> The full reviews are attached below and I have briefly summarized the major concerns here.
>
> 1\) Lack of computational or experimental validation. The specific examples mentioned as potential future directions do not help that much in evaluating the overall reliability of the predictions made by this approach. The authors should consider whether or not there are suitable gold-standards; for example, the \>50 drugs that are already known to be metabolized by human gut bacteria. Alternatively, they could use as positive controls structural analogs like altretamine and melamine, to see if these chemical pairs always result in similar predictions. The authors might also test if their unbiased clustering recapitulates established chemical classes. In addition to these more global analyses of specificity, sensitivity, and precision, we would like to see at least one of the novel predictions validated experimentally (if possible within the time frame).

Computational validation

We agree that computational validation is vital to demonstrate the value of the MicrobeFDT resource. To computationally validate MicrobeFDT, we 1) demonstrate that our structural similarity metric can identify a) shared enzyme metabolism and b) shared drug toxicity; 2) show that our clustering recapitulates established chemical classes; and 3) perform an out-of-sample validation to demonstrate high substructure overlap correlates with enzyme specificity.

1a) Assessing the correlation between compound structural similarity and shared enzyme metabolism.

We characterize how well the structural similarity metric in MicrobeFDT enables identification of compounds that share metabolism by an enzyme and demonstrate that structural similarity can be used as filter to identify shared metabolism.

"To validate that our network can identify shared metabolism, we developed an *in silico* prediction model to assign a probability of shared metabolism between compounds based on substructure overlap and the following physiochemical categories: geometry, functional groups, amino acid composition, polarity and hydrophobicity. We find that the probability of compound-pairs sharing an enzyme based on substructure and physiochemical parameters increase as the substructure overlap score between compound pairs increases (Figure 2). Weighting compound pair chemical similarity relationships based solely on substructure similarity is thus a reasonable filtering step to identify compounds that may share metabolism.

"Predicting the probability of association of compound pairs both serving as substrates for an enzyme based on substructure and physiochemical parameters.

Each compound pair was assigned one of two labels, associate or non-associated, based on whether both compounds are substrates for the same enzyme (associated) or not (non-associated), given compound-enzyme relationships in the KEGG database^102^. The DataWarrior program^103^ was used to identify the following parameter categories for each compound: geometry, functional groups, aromaticity, amino acid composition, polarity and hydrophobicity. In order to translate compound pair substructure and physiochemical parameters into a probability of overlapping metabolism we used a machine learning approach for generating probability estimates for multi-class classification problems^104,105^. Briefly, this approach builds a multi-class prediction model by using pair-wise coupling. We then implemented the prediction model using the probsvm package in R using a one-vs-one decomposition scheme^104^"

1b) Assessing the correlation between structural similarity and toxicity similarity.

To evaluate whether our network also recapitulates shared drug toxicity found in earlier studies (Campillos et al., 2008) we fit a linear regression and computed the effect size to assess the association between substructure similarity and toxicity similarity for therapeutic drugs in our network.

"Previous studies have found that structural similarity predicts both toxicity and drug target similarity^44^. To evaluate whether our network also recapitulates shared drug toxicity we fit a linear regression and computed the effect size to assess the association between substructure similarity and toxicity similarity for therapeutic drugs in our network. We find that structural similarity moderately positively predicts toxicity similarity for therapeutic drug pairs linked by structural similarity overall in the network; the signal is stronger at higher structural similarity (r = 0.03116, p \< 2.2e-16) (Figure 4)."

"Pair-wise toxicity similarity between drugs was computed based on summing the products of weights over all shared side effect concepts between drug pairs. We fit a linear regression to determine whether there is a linear relationship between compound pair substructure similarity and toxicity similarity."

2\) Clustering validation

We demonstrate that our clustering recapitulates established chemical classes. For clusters of compounds in the chemical similarity network we evaluated how often they recapitulate structure-based chemical taxonomy as defined by the ClassyFire resource, a comprehensive chemical classification schema. We found that substructure-based compound clustering, significantly groups compounds within a ClassyFire superclass based on a comparison of the MicrobeFDT network with a randomized network with the same number of nodes and edges.

"Finally, we evaluated how well our compound clustering recapitulates structure-based chemical taxonomy as defined by the ClassyFire^45^ resource, a comprehensive chemical classification schema, at the level of superclass taxonomy. We found that substructure-based compound clustering, significantly groups compounds within a ClassyFire superclass based on a comparison of the MicrobeFDT network with a randomized network with the same number of nodes and edges (p \< 8.06 x 10-15, Wilcoxon rank-sum test). Compound-pairs at higher substructure similarity share Superclass membership at higher substructure values and at a greater frequency than randomized pairs, indicating that the MicrobeFDT substructure similarity metric can capture established chemical classifications (Figure 5)."

"Assessment of compound substructure-based clustering recapitulation of chemical ontology.

The MicrobeFDT substructure similarity network is defined by the Tanimoto coefficient of the PubChem 2D molecular fingerprint representations between two compounds^3839^. To assess how well compound substructure-based clustering recapitulates chemical ontology we compared network features between the MicrobeFDT substructure similarity network and randomized network with the same number of nodes, edges and labels. Each compound label includes a ClassyFire schema derived hierarchical set of chemical descriptors. The chemical similarity network was rendered in Cytoscape using NetworkRandomizer^1^. Using the Wilcoxon rank-sum test we compared superclass level chemical descriptors across connected compounds between the real and random network. For the MicrobeFDT network, we also computed the ratio of compounds pairs with matched Superclass annotation to unmatched annotations for all pairs with the same substructure score to assess the relationship between substructure similarity and shared chemical ontology."

3\) Out of sample validation of compound-enzyme interactions.

We do an out-of-sample validation by assessing substructure overlap of compounds in the network with digoxin, a cardiac glycoside drug and a substrate of the Cgr2 enzyme. This microbial enzyme has the most complete drug substrate profile to our knowledge and we therefore selected it to demonstrate the utility of a substructure similarity screen to identify compounds that might interact with the same enzyme.

"As an example of how the network can reveal shared metabolism we selected compounds in the network with substructure overlap with digoxin, a cardiac glycoside. Reduction of digoxin by a human microbiome reductase inactivates the drug, contributing to poor bioavailability in some individuals^5,9,42^. Koppel et al., biochemically characterized the capacity of a single flavin- and \[4Fe-4S\] cluster-dependent reductase, *cgr2*, to reduce various substrates with a range of substructure similarity to digoxin^43^. We identified the substructure overlap between digoxin and compounds in the Koppel et al. study that were evaluated as substrates of Cgr2 enzyme. Among the biochemically assayed compounds^43^ that are present in the MicrobeFDT network, compounds with substructure similarity scores greater than 0.8 are also substrates for Cgr2. This assessment suggests that for the cgr enzyme substructure based clustering can distinguish experimentally characterized substrates from non-substrates (Figure 3)."

Together, these additional analyses and figures validate the computational methods used to build MicrobeFDT.

Experimental validation of the MicrobeFDT resource.

As noted by the reviewers, experimental validation is a major undertaking. We agree with the reviewers that experimental validation is also necessary to demonstrate that MicrobeFDT can identify novel, potentially biologically and clinically relevant microbiome/compound interactions. Sarah Wolfson, a postdoc in the Kelly lab, was instrumental in these experiments and we have added her as a coauthor to the manuscript. A combination of features in MicrobeFDT indicates that altretamine, an ovarian cancer drug, may be demethylated by N-demethylase enzymes in the microbiome. This prediction comes from structural overlap, toxicity similarity, and inferred enzyme/compound interactions from the network. We validated microbiome metabolism of altretamine by incubating altretamine in a pooled fecal slurry generated from three individuals and monitored altretamine and potential metabolites using LC-MS/MS. We found that a metabolite that is structurally identical to pentamethylmelamine, a demethylated altretamine metabolite, increases in active fecal microcosms over 48 hours. We thus experimentally validate a novel microbiome/drug interaction predicted by MicrobeFDT.

"A first step in validating this hypothesis is to demonstrate that the gut microbiome can demethylate altretamine. We incubated altretamine in a pooled fecal slurry generated from three individuals and monitored altretamine and potential metabolites using LC-MS. We controlled for the formation of spontaneous N-demethylation of altretamine, which has been reported in the literature^58^, and found that a metabolite that is structurally identical to pentamethylmelamine, a demethylated altretamine metabolite, increases in active fecal microcosms over 48 hours (Figure 9). In active fecal biotic conditions the metabolite continually increased between time 0 and 48 hours. Killed controls demonstrated an increase in metabolite between 0 and 24 hours, though to a lesser extent than in active fecal microcosms. Notably there was little metabolite formation after 24 hours, indicating that in addition to abiotic N-demethylation, active gut microbes demethylate a substantial portion of altretamine to the putative metabolite pentamethylmelamine."

"Altretamine microbiome turnover validation

Collection and preparation of fecal samples:

Fresh fecal samples were provided by 3 healthy adult men aged 23-30 with no history of antibiotics for 6 months prior to the study. \[...\] Elution occurred at 0.35 ml/min with 100% A for 1 minute, followed by a 1.5 minute linear gradient from 100% A to 95% B, and finally 100% B for 1 minute. The voltage was set to 0.044 kV."

> 2\) Structural similarity could be misleading. The major caveat to this approach is that overall similarity can be thrown off by differences in parts of the molecules that are irrelevant for the enzymatic activity. This can lead to false positives (compounds with similar overall structure but differences in the relevant sub-structure) and false negatives (compounds with different R groups but the same core chemical motif). While solving this problem may be beyond the scope of this analysis, we would like to see it acknowledged and some analysis to determine how big a problem this is for the current set of predictions.
>
> Numerous research groups work in this area with a higher degree of sophistication, and likely accuracy, than this paper describes (see citations from reviewer 2). Each of the tools above allows compounds to be linked to reactions; none are mentioned in this paper; and none of them rely on simply using a chemical fingerprint as the likelihood that a drug would participate in a chemical reaction. Chemical fingerprints are not intended for asserting that a molecule would be compatible with a chemical reaction. If we understand the algorithm correctly, we don\'t think it is appropriate for scoring biochemical-reaction promiscuity. We recommend completely overhauling this part of the algorithm.
>
> In the examples that the authors show, leucovorin is strongly clustered with ambenonium which differ in structure. Similarly, metformin and atretamine are very different molecules -- even though they are rich in Nitrogen. Furthermore, not every chemical moiety can be undone-just because a molecule has a methyl group doesn\'t mean that it can be demethylated.

The reviewers pointed out several additional major issues with our work and we address below 1) how our compound-enzyme interactions are defined and 2) our decision to use a chemical fingerprint to assess structural similarity among compounds. We agree with the reviewers that the fingerprint is not suitable for scoring biochemical-reaction promiscuity.

1\) Compound-enzyme link clarification

We regret that it was unclear that the network does not predict the links between compounds and enzymes; rather these links in the network are derived from published annotations in the Kyoto Encyclopedia of Genes and Genomes (KEGG).

We indicate in the text compound and enzyme links are generated from available resources as follows: "To link microbial enzymes to the set of compounds they metabolize we used KEGGREST (v1.14.1) to retrieve KEGG compound identifiers with links to Enzyme Commission numbers, metabolic modules and pathways, and presence in either organisms listed as microbial or *Homo sapiens^97^*."

We agree with the comment "not every chemical moiety can be undone" and we agree that the fingerprint is not suitable to predict biochemical-reaction promiscuity. These two comments underlie why we did not attempt to predict novel compound/enzyme associations in MicrobeFDT but rather developed the resource to shrink the search space of potential compound/enzyme interactions for users.

For the altretamine example, we hypothesize that N-demethylase/altretamine interactions contribute to drug toxicity based on the observations that 1) altretamine clusters structurally with melamine; 2) altretamine and melamine have similar toxicities in MicrobeFDT; and 3) altretamine is linked in the network to microbial N-demethylases.

"To provide a practical example of using multiple features of MicrobeFDT to identify uninvestigated microbiota-driven drug toxicity, we searched the network for compounds with high structural and toxicity similarity. \[...\] We hypothesized that gut microbial N-demethylases may partially or completely N-demethylate altretamine, converting it into metabolites that contribute to patient toxicity."

Importantly, the network does not predict demethylation. For all compounds in the network enzymatic activity is described only by existing annotations in KEGG. Rather the network reveals structural and toxicity similarity of these two compounds and we use these features to hypothesize a mechanism by which N-demethylases may act on the compound to produce toxic intermediates. The power of MicrobeFDT is that it connects structural similarity with biochemistry, toxicity, and microbial ecology and we have corrected our presentation of the work in the revision to clarify that structural similarity is not intended to be the sole basis of a prediction.

"The chemical space of the human gastrointestinal tract ecosystem is shaped by host dietary intake, xenobiotic exposure, and host and gut microbiome derived products. \[...\] We used a combination of network features to successfully predict the novel microbial metabolism of the cancer drug altretamine."

2\) The strengths and limitations of the chemical fingerprint as the foundation for the structural similarity network.

We agree that overall structural similarity, as defined by the chemical fingerprint approach we take, does not prioritize fragment substructures based on susceptibility to enzyme mediated chemical modifications or take into account the active moieties of a compound. We have included extensive revisions to the manuscript to address these points. (New figures 2, 3, 4, 5, 9; text revisions as described above)

The reviewers also point to the role of enzyme promiscuity in shaping the probability that two chemically overlapping compounds will be processed by the same enzyme. To include enzyme promiscuity in MicrobeFDT we will discuss extracting data from resources like RetroRules^9^ (mentioned by the reviewers), which uses SMARTS strings to define reaction rules, and/or the Promis server. The Promis server provides a measure of enzyme multifunctionality that could further support a user's ranking of hypothesized compound-enzyme interactions. We agree with the reviewers that it is important to describe the many issues with defining structural similarity between molecules. We describe these alternative chemical reaction prediction and discuss possibilities for improving the inference of biochemical interactions between molecules and enzymes in future iterations of the resource.

"A combination of compound, host, and microbiome features influence potential microbial metabolism. Examining these features individually cannot reliably infer clinical phenotypes associated with microbiome/compound interactions. Two molecules may have the same toxicity profile but very different biochemistry, for example. Automated enzyme annotation may be incorrect, and compound structural similarity is often insufficient to predict substrate preferences. Finally, enzymes that carry out a reaction associated with a patient phenotype may be unevenly distributed across microbes and across human microbiomes. MicrobeFDT is designed to overcome some of these limitations by enabling a more holistic analysis of toxicity, structure, metabolism and ecology."

"MicrobeFDT does not predict substrate specificity for microbiome enzymes; available data and methods are not sufficient to achieve this goal. Enzyme promiscuity also shapes the probability that two chemically overlapping compounds will be processed by the same enzyme. A future improvement to our resource could extract data from resources like RetroRules^91^, which uses SMARTS strings to define reaction rules, or utilizing the Promis server measure of enzyme multifunctionality^92^ to further support a user's ranking of hypothesized compound-enzyme interactions."

> 3\) Clustering by toxicity could also be misleading. The logic here is not clear, since there could be many reasons for why two molecules show the same toxicity profile -- most of which will have nothing to do with the microbiome or with metabolism more broadly. For example, two completely different antidiabetic drugs may have the same side effect, hypoglycemia. A diuretic and a smooth muscle relaxant may have the same side effect, hypotension, etc.

We agree that some side effects are common across drugs with different metabolic pathways. For this reason, we used a measure of toxicity similarity that weights side effects based on frequency, correlation and co-dependence across all compounds in our dataset; this approach has been experimentally tested to predict previously unknown molecular interactions based on side-effect data^2^. We also agree that it is important to address the limitations of clustering compounds by toxicity alone. Again we regret that we were unclear that toxicity profiling is only one part of the MicrobeFDT resource and it is not intended to be used as the sole feature on which to make a prediction of drug/microbiome interactions. Our changes that validate toxicity clustering, and the importance of using multiple features in MicrobeFDT to make a prediction, are detailed above.

> 4\) ECs are broad groups of enzymes that do not adequately capture substrate preferences. It\'s unclear to us how the EC analysis would be used in practice. For example, let\'s consider the case of altretamine and N-demethylases. These enzymes are widespread in bacterial genomes and have broad substrate scope as a family. Which one (if any) can metabolize the drug? Just because an enzyme has an EC annotation of ligase, hydrolase, oxidoreductase, doesn\'t mean that a molecule with certain functional groups can be a substrate to it. It doesn\'t even mean that it is correctly annotated.

We agree that the EC number does not capture substrate specificity and we agree that microbial enzymes in the gut are widespread and can have broad substrate scope. We clarify that MicrobeFDT does not predict substrate specificity and we discuss why it is useful to assess how widespread the distribution of a function of interest in the gut.

"An important step towards characterizing the role of the gut microbiome in shaping individual responses to foods and drugs is identifying how gut microbiome metabolism varies from compound to compound and how this metabolism relates to inter-personal variation in diet or drug responses to specific compounds. \[...\] The ECs~D~ score is a readout of potential substrate metabolism at the community level that can be linked to inter-personal variation in gut function and phenotypic outcomes."

"MicrobeFDT does not predict substrate specificity for microbiome enzymes; available data and methods are not sufficient to achieve this goal. Enzyme promiscuity also shapes the probability that two chemically overlapping compounds will be processed by the same enzyme. A future improvement to our resource could extract data from resources like RetroRules^91^, which uses SMARTS strings to define reaction rules, or utilizing the Promis server measure of enzyme multifunctionality ^92^ to further support a user's ranking of hypothesized compound-enzyme interactions."

We do not attempt to predict which N-demethylases act on altretamine. We agree with the reviewers that there are many N-demethylases in the human microbiome (Figure 4---figure supplement 1) and it is not possible to predict computationally which specific enzymes are interacting with a compound of interest. As noted by the reviewers, there are many other widely distributed enzymes with broad substrate scope in the microbiome. To discuss another example, we do not predict all the carbohydrates that a particular carbohydrate active enzyme in the microbiome, such as a beta glucuronidase, acts on. We also agree, and will note in the revision, that there are likely misannotations in the databases we are using that incorrectly ascribe functions to particular enzymes.

"Automated enzyme annotation may be incorrect, and compound structural similarity is often insufficient to predict substrate preferences."

We hope it is now clear in the text that MicrobeFDT does not predict substrate specificity for all microbiome enzymes; both our methods and the available data make it impossible to achieve this goal currently. But as also noted by the reviewers, our resource is a vital, missing first step towards this goal.

The examples of potential food/drug interactions with SN-38G metabolism by the gut and potential antimicrobial effects of bile salt-like compounds are biologically reasonable examples of novel hypotheses of microbiome/food/drug interactions that MicrobeFDT can generate. These vignettes are intended as starting points for experimental characterization but they also indicate ways for a user to interact with MicrobeFDT to generate hypotheses with the starting point of a specific compound (like SN-38G) or with a very broad function (like antimicrobial activity). We therefore request that we be allowed to leave these examples as part of the manuscript.

We hope that we have sufficiently addressed reviewer 2's major concerns regarding "The validity of their major claims and using chemical fingerprint as a proxy for reactivity given alternative approaches." in the revisions described above.

The revisions and responses above also address reviewer 3's major concerns about how we 1) define the chemical space of xenobiotics that the human microbiome is exposed to; 2) cluster molecules based on their reported toxicities; and 3) identify biochemically relevant and functionally plausible microbe-compound interactions. We hope that computational and experimental validation of MicrobeFDT moves reviewer 3 to now see the value in our resource.
